takeda_usa_pharmaceuticals_u

Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

pharmafile | March 11, 2020 | News story | Research and Development, Sales and Marketing |  Ninlaro, Takeda, multiple myeloma, pharma 

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed transplant ineligible multiple myeloma, revealing that the therapy, when combined with lenalidomide and dexamethasone, unfortunately did not meet its primary endpoint.

The combo was shown to improve median progression-free survival by 35.3 months compared to 21.8 months with lenalidomide and dexamethasone alone – an overall improvement of 13.5 months, but this was not to a degree that was considered statistically significant.

The combo’s safety profile was found to be in line with previous research.

“There is a need for treatment options in transplant ineligible patients. We remain committed to advancing the field of multiple myeloma and continue to drive innovation through ongoing research and development,” said Christopher Arendt, Head of Takeda’s Oncology Therapeutic Area Unit. “We are confident there will be numerous learnings from this trial and look forward to sharing these data with the community. We want to thank the patients and investigators for their participation in this important programme.”

Advertisement

The full results of the study will be revealed at an upcoming medical event, Takeda confirmed.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

The Gateway to Local Adoption Series

Latest content